Inteum Company
Links
seedsprint
Visible Legacy
RSS
News & Resources
Inteum Company News
Inteum Library
Subscribe
Search Results - technology+classifications+%3e+therapeutics
237
Results
Sort By:
Published Date
Updated Date
Title
ID
Descending
Ascending
Identification of NFAT5 as a novel target for preventing KRAS targeted therapy resistance
Inhibiting NFAT5 attenuates pancreatitis-induced resistance to KRAS inhibition and extends mouse survival. Invention Summary: Resistance to KRAS targeted therapy in cancers involves epithelial-to-mesenchymal transition (EMT), which poses challenges for effective targeting. However, the mechanism underlying EMT associated KRAS resistance...
Published: 1/6/2025
|
Inventor(s):
Pingping Hou
,
Daiyong Deng
Keywords(s):
Anti-cancer
Category(s):
Technology Classifications > Cancer
,
Technology Classifications > Healthcare & Life Sciences
,
Technology Classifications > Therapeutics
High-Throughput Approach to Identify New Lipid Nanoparticle Formulations for Vaccine and Drug Delivery
High-throughput in vivo screening method to identify lipid nanoparticle (LNP) formulations for local and systemic delivery for mRNA vaccines and cancer immunotherapies. Problem: Nucleic acid delivery is an attractive and rapidly growing area of research, particularly for the development of vaccines and cancer immunotherapy. Historically, viral vectors...
Published: 12/20/2024
|
Inventor(s):
Michael Mitchell
,
Alex Hamilton
Keywords(s):
Bioengineering
,
COVID-19
,
Drug Delivery
,
Gene Therapy
,
Immunology
,
Immunoncology
,
Immunotherapy
,
Infectious Disease
,
Nanotechnology
Category(s):
Technology Classifications > Testing & Measurement
,
Technology Classifications > Vaccines
,
Technology Classifications > Therapeutics
T-Cell-Activating Lipid Nanoparticles for Rapid Engineering of CAR T Cells
A method to streamline the process of generating chimeric antigen receptor (CAR) T cells for therapeutic applications. Problem: CAR T cell therapy has demonstrated clinical success in treating various forms of cancer. With more CAR T cell therapies projected to gain regulatory approval, manufacturing becomes increasingly important in the face of this...
Published: 12/20/2024
|
Inventor(s):
Ann Metzloff
,
Margaret Billingsley
,
Michael Mitchell
Keywords(s):
Bioengineering
,
Cell Therapy
,
Drug Delivery
,
Immunoncology
,
Immunotherapy
,
Oncology
,
Platform Technology
Category(s):
Technology Classifications > Therapeutics
Prodrug Lipid Nanoparticles for Synergistic Cancer Immunotherapy
Prodrug lipid nanoparticle (LNP) with a mRNA encoding for a therapeutic cytokine for solid tumor immunotherapy.</brief> Problem: Approximately 2 million people are diagnosed with cancer each year in the United States. Messenger RNA (mRNA)-based cancer immunotherapy has emerged as a potential cancer treatment using cytotoxic T cells to eliminate...
Published: 12/20/2024
|
Inventor(s):
Michael Mitchell
,
Qiangqiang Shi
Keywords(s):
Bioengineering
,
Drug Delivery
,
Oncology
,
Platform Technology
Category(s):
Technology Classifications > Therapeutics
Method to Alleviate Side Effects of CAR T Cell Immunotherapies
CAR-T cells are PEGylated to block the interactions with monocytes and macrophages to reduce the side effects of CAR-T cell therapies (cytokine release syndrome and neurotoxicity). Problem: CAR-T cell therapies lead to many adverse side effects such as cytokine release syndrome (CRS) and neurotoxicity. It has been shown that 20-70% of patients receiving...
Published: 12/20/2024
|
Inventor(s):
Michael Mitchell
,
Ningqiang Gong
Keywords(s):
Bioengineering
,
Cell Therapy
,
Immunology
,
Immunoncology
,
Immunotherapy
,
Oncology
Category(s):
Technology Classifications > Chemical Processes and Synthesis
,
Technology Classifications > Therapeutics
Macrophage-Targeting Lipid Nanoparticles (MacLNPs) Deliver siRNA Intranasally to Treat Viral Pneumonia
siRNA-LNP knock-down of TAK1 delivered intranasally and to macrophages specifically prevents inflammation-induced pathology in a mouse model Problem: Macrophages are an important component of the innate immune system, but can mediate excessive inflammation and cause severe pathology if left unchecked. This poses a challenge for the treatment of acute...
Published: 12/19/2024
|
Inventor(s):
Michael Mitchell
,
Lulu Xue
,
Andrew Vaughan
,
Gan Zhao
Keywords(s):
Bioengineering
,
Drug Delivery
,
Gene Therapy
,
Immunology
,
Infectious Disease
,
Inflammation
,
Nanotechnology
,
Platform Technology
Category(s):
Technology Classifications > Chemical Processes and Synthesis
,
Technology Classifications > Materials
,
Technology Classifications > Therapeutics
,
Technology Classifications > Vaccines
Overcoming the Blood-Brain Barrier with Peptide-Functionalized Lipid Panoparticles
Peptide-functionalized lipid nanoparticles (pLNPs) for targeted messenger RNA (mRNA) delivery to the brain. Problem: Ionizable lipid nanoparticles (LNPs) have emerged as clinically advanced delivery vehicles for nucleic acids. However, as LNPs typically accumulate to the liver, tissue-specific delivery remains challenging, and systemic LNP delivery...
Published: 12/19/2024
|
Inventor(s):
Michael Mitchell
,
Emily Laura Han
Keywords(s):
Bioengineering
,
Drug Delivery
,
Neurodegenerative Diseases
Category(s):
Technology Classifications > Therapeutics
Targeted In Utero Therapeutics Delivery System for Precise Gene Editing
Targeted lipid nanoparticles (LNPs) that can deliver mRNA-based gene editing therapeutics to hematopoietic stem cells (HSCs) in utero Problem: Monogenic blood diseases, including sickle cell disease and / thalassemia, are among the most prevalent genetic conditions worldwide, causing significant pediatric morbidity with complications like painful...
Published: 1/2/2025
|
Inventor(s):
Rohan Palanki
,
Michael Mitchell
,
William Peranteau
Keywords(s):
Bioengineering
,
Gene Editing
,
Gene Therapy
,
Platform Technology
Category(s):
Technology Classifications > Therapeutics
MYC Program as a biomarker of response to treatment with Enzalutamide
Invention Summary: Administration of Enzalutamide has been shown to improve patient survival overall, yet patients respond differently to the drug with nearly half either not responding or developing resistance over time. Unfortunately, patients that fail Enzalutamide treatment are left with no targeted therapeutic option, and progress to...
Published: 12/12/2024
|
Inventor(s):
Keywords(s):
Category(s):
Technology Classifications > Cancer
,
Technology Classifications > Diagnostics
,
Technology Classifications > Healthcare & Life Sciences
,
Technology Classifications > Therapeutics
Tirzepatide and other GLP1RA as a novel treatment for patients with congenital generalized lipodystrophy
The image represents the mechanism of action of Tirzepatide. Image courtesy: Rabbani et al., 2024 Invention Summary: Congenital generalized lipodystrophy (CGL) is a rare autosomal recessive disorder, affecting approximately 1 in 10 million...
Published: 12/5/2024
|
Inventor(s):
Christoph Buettner
,
Svetlana Ten
Keywords(s):
Category(s):
Technology Classifications > Healthcare & Life Sciences
,
Technology Classifications > Therapeutics
1
2
3
4
5
6
7
8
9
10
...